Search
Norfloxacin
go.drugbank.com/drugs/DB01059ApprovedInvestigationalA synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP3A InhibitorsProducts: NORFLOXACINA DR. REDDY'S, NORMED 400 - UEverolimus
go.drugbank.com/drugs/DB01590ApprovedInvestigationalEverolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a simi...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: EVEROLIMUS DR. REDDY'SUrsodeoxycholic acid
go.drugbank.com/drugs/DB01586ApprovedInvestigational[A256272] Due to its hydrophilicity, UDCA is less toxic than [cholic acid] or [chenodeoxycholic acid].
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 Enzyme InducersProducts: Urso DS, PRESTALIX AUNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsSildenafil
go.drugbank.com/drugs/DB00203ApprovedInvestigationalIn eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) . The result of doing so allows cGMP pre...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazineSitagliptin
go.drugbank.com/drugs/DB01261ApprovedInvestigationalSitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication ...
Mixtures: ARGLIPTIN-D, LIBERECO-DXCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesRaxibacumab
go.drugbank.com/drugs/DB08902ApprovedInvestigationalRaxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons.
Synonyms: PA mAbLevocetirizine
go.drugbank.com/drugs/DB06282ApprovedInvestigationalLevocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms. It is the R enantiomer of cetirizine. Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine. Levocetirizine w...
Mixtures: ANTISS® D, ANTISS® DCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAtropine
go.drugbank.com/drugs/DB00572ApprovedInvestigationalVet approvedIt is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.
Mixtures: PB Hyos, Re-PB HyosSynonyms: dl-Hyoscyamine, dl-tropyltropateCosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalCosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the
Synonyms: anti-Pd-l1 monoclonal antibody CK-301, IMMUNOGLOBULIN G1-LAMBDA, ANTI-(HOMO SAPIENS PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1, CD274 ANTIGEN))HUMAN MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-450) (HOMO SAPIENS VH (IGHV1-69*01 (94%) (IGHD)-IGHJ1